The Federal Trade Commission is probing CVS Caremark , Express Scripts Inc. and other large pharmacy-benefits managers over what impact their business models have on the accessibility and affordability of prescription drugs.
The FTC on Tuesday said it would require the six largest PBMs, which negotiate rebates and fees with drug manufacturers, to provide records and other information about their business practices. The documents will be used to conduct a study of the PBM industry, the FTC said. The compulsory orders are also being sent to UnitedHealth Group Inc.’s OptumRx Inc., Humana Inc., Prime Therapeutics LLC and MedImpact Healthcare Systems Inc.
An Eliquis rep appeared the same day this announcement was made to inform me BCBS will “suddenly” allow Eliquis to return to my patients’ formulary after being switched to Xarelto earlier this year. Coincidence? Doubt it.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.